Warfarin genes do not replace the INR record

A pharmacogenomic report and an INR result can sit beside each other in the same folder without measuring the same thing. The gene report supplies inherited information that may be relevant to prescribing. INR is a monitoring measurement used in anticoagulation care. Treating either document as a replacement for the other loses useful information.

The 2017 CPIC warfarin guideline includes genetic and non-genetic factors within a defined clinical framework. It is not a two-gene shortcut that a reader can turn into a personal dose. This article deliberately supplies no dosing formula, calculation or target INR.

Prediction and monitoring belong on different lines

In a fictional example, Alex has an older report naming CYP2C9 and VKORC1 and a newer anticoagulation appointment letter. Alex wonders whether the DNA result means the blood test is unnecessary. The useful question for the care team is how the inherited information fits into the current monitoring plan, not whether one document cancels the other.

Alex keeps the report date and the dates of monitoring results separately. A gene finding does not acquire a new value each time a blood test is taken. A monitoring result describes a particular measurement, not a new genotype. Separating these timelines prevents a stable genetic label from being mistaken for evidence that treatment effects are stable today.

The two gene names also should not be treated as interchangeable. They relate to different aspects of the medicine’s biology. A panel showing both names still requires its actual assignments, tested coverage and clinical interpretation. Merely spotting both headings does not show that all relevant information has been measured.

The clinical framework has a scope

The CPIC publication specifies settings and populations for its guidance and discusses additional factors. A consumer-facing article should not detach an equation from that framework or fill missing inputs with guessed values. A precise-looking number can be misleading if its applicability has not been established.

This is especially important when an online calculator asks for information a reader does not know. Filling every box is not the same as having appropriate clinical evidence. Unknown laboratory coverage, an uncertain allele assignment or an unverified indication should remain unknown. A report-reading note can expose these gaps without trying to solve the prescribing decision.

The NHS warfarin information places the medicine within ongoing care and monitoring. Its public information is a better place to orient a reader than a copied dosing table. Use the anticoagulation service’s current instructions for the actual treatment plan rather than selecting a schedule from general material.

Current context still matters

The NHS Specialist Pharmacy Service’s warfarin monitoring page stresses an individualised monitoring plan and the relevance of factors such as interacting medicines and changes in health. It is professional guidance, not a self-adjustment tool. We use its monitoring context, not its dose-management instructions.

A fictional timeline might show a gene report in February, a newly prescribed medicine in June and an INR measurement in July. Those entries help a clinician ask the right questions. They do not establish that the new medicine caused a particular measurement. Dates provide context; they are not proof of causation.

Keep medicine names and changes in the record as the treating team requests. If a detail is uncertain, mark it as uncertain. It is more useful to bring an incomplete but honest timeline than a smooth story constructed after reading a gene association online.

Prepare one joined-up question

Try: “Do you have this genetic report, and how is it being considered alongside my current INR monitoring?” Include the laboratory, report date and full assignment rather than only the gene names. Ask where the explanation will be recorded so it is available at later reviews.

If the team has already given a plan, keep that plan distinct from the general report summary. A past interpretation is not a permanent instruction to disregard new monitoring or symptoms. A saved genetic document cannot observe changes in treatment, diet, illness or other circumstances.

The takeaway is a two-part folder: inherited report information on one side, current monitoring and professional instructions on the other. Both can be useful. Neither is a licence to calculate, skip or change treatment independently, and a short gene label should never overwrite the current anticoagulation record.

Scope and source access

Research accessed 4 October 2026: the CPIC guideline PDF, NHS medicine page and SPS monitoring page, updated December 2025. No personal target, dose, algorithm or schedule is provided. Existing care-team instructions remain authoritative for an individual’s treatment.